Benitec and Biotron in the race for $3.5b Hepatitis B market

Chronic Hepatitis B, a currently incurable disease, is attracting growing attention among international biotechs. The World Health Organisation estimates 257 million people live with Hep B and up to 900,000 die each year from related diseases such as liver cancer and cirrhosis. In Australia, more than 232,000 people have chronic hepatitis B, according to lobby group Hepatitis Australia. “Deaths from primary liver cancer have been climbing faster tha

Biotron Phase 2 Hepatitis C Trial Success

- HCV genotype 1 patients treated with BIT225 and Interferon/Ribavirin (IFN/RBV) significantly more likely to clear virus than those treated with IBN/RBV alone- Major advance in capsule form of BIT225- BIT225 safe and well toleratedNEW YORK, March 17, 2016 /PRNewswire/ -- Biotron Limited (ASX: BIT) confirms positive outcomes from its Phase 2 study of its first-in-class antiviral drug BIT225.The trial was designed to assess the safety and antiviral activity...